<DOC>
	<DOCNO>NCT00704080</DOCNO>
	<brief_summary>The purpose study determine safety tolerability XL765 combination Temozolomide adults anaplastic glioma glioblastoma stable Temozolomide maintenance dose . XL765 new chemical entity inhibit kinase PI3K mTOR . In preclinical study , inactivation PI3K show inhibit growth induce apoptosis ( program cell death ) tumor cell , whereas inactivation mTOR show inhibit growth tumor cell . Temozolomide ( TMZ , TemodarÂ® ) orally administer alkylating agent activity malignant glioma . It approve Food Drug Administration follow indication : 1 ) treatment newly diagnose glioblastoma multiforme ( GBM ) patient give concomitantly radiotherapy maintenance treatment ; 2 ) refractory anaplastic astrocytoma ( AA ) , ie , patient experience disease progression drug regimen contain nitrosourea procarbazine . Temozolomide commonly use treatment anaplastic glioma ( AG ) include oligodendroglial tumor mixed glioma .</brief_summary>
	<brief_title>A Study XL765 ( SAR245409 ) Combination With Temozolomide With Without Radiation Adults With Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically confirm intracranial Grade 3 4 anaplastic glioma glioblastoma ( astrocytic tumor , anaplastic oligodendroglioma , oligoastrocytoma ) Received prior standard radiation Grade 3 4 astrocytic tumor minimum cumulative dose 40 Gy administer Completed least one full cycle temozolomide 200 mg/m2/day administer Days 15 28day cycle , without unacceptable toxicity progression Karnofsky performance status 60 Adequate organ bone marrow function define hematological serum chemistry limit At least 18 year old . Both men woman must practice adequate contraception Informed consent Progressed temozolomide Evidence acute intracranial intratumoral hemorrhage &gt; Grade 1 Restriction therapies/medications within specific timeframes prior enrollment study include cytotoxic chemotherapy temozolomide , biologic agent , nitrosoureas mitomycin C , smallmolecule kinase inhibitor , noncytotoxic hormonal agent , prior therapy PI3K inhibitor , radiation therapy , enzymeinducing anticonvulsant , valproic acid Not recover toxic effect prior therapy Pregnant breast feed History diabetes mellitus Uncontrolled intercurrent illness Congestive heart failure , unstable angina , myocardial infarction within 3 month enter study . HIV positive Diagnosis another malignancy may exclude subject study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>GBM</keyword>
	<keyword>Anaplastic glioma</keyword>
</DOC>